Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With SGLT2 Inhibitors vs Metformin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin: A Cohort Study
Ann. Intern. Med 2022 May 24;[EPub Ahead of Print], H Shin, S Schneeweiss, RJ Glynn, E PatornoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.